PolymarketVerfügbarkeit prüfenKein KYC2% GebührAktuelle implizite WahrscheinlichkeitJa 12%-0.0%
Marktqualitat
52 / 100
Mittlere Qualität24h-Volumen
238,8 €
Liquidität
2430,2 €
Mittlere LiquiditätGeld / Brief
11.0% / 12.0%
Spread
9.1%
Breiter Spread7d-Änderung
-4.5%
Marktdaten
Aktualisiert vor 5 Minuten
12. Jan. 26, 23:0931. Dez. 26, 0:00
Trends
Gewähltes Ergebnis
Yes12%
Auch verfügbar auf Kalshi
Will the FDA approve retatrutide?
11.0%6Mon
-11.0%17%
-7.0%85%
-7.0%87%
+2 weitere Ergebnisse
28 • Niedrige QualitätBreiter SpreadNiedrige LiquiditätDünner Markt
Gesamtvolumen102 €
24h-Volumen5,1 €
KALSHIRegeln
Retatrutide is a triple agonist hormone/peptide drug developed by Eli Lilly and currently in trial to treat obesity, fatty liver disease, type-2 diabetes, knee osteoarthritis, and more.
- This market will resolve to "Yes" if the U.S.
- Food and Drug Administration (FDA) grants a full or conditional approval for Eli Lilly’s for a drug product whose active ingredient is Eli Lilly’s retatrutide (including any brand name or identifier such as LY3437943) for any use between market creation and December 31, 2026, 11:59 PM ET.
- Otherwise, this market will resolve to "No."
- An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application
- The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs
Wahrscheinlichkeiten können aufgrund unterschiedlicher Marktstrukturen, Gebühren und Teilnehmerpools abweichen.
Verwandte Märkte
Hantavirus pandemic in 2026?
145.259,6 €Ja: 5%POLYMARKET
POLYMARKET
New pandemic in 2026?
16.626,4 €Ja: 10%POLYMARKET
POLYMARKET
Ebola pandemic in 2026?
8708 €Ja: 8%POLYMARKET
POLYMARKET
How many movies will gross >$1 billion in 2026?
1257,8 €0-3: 5.7%MANIFOLD MARKETS
MANIFOLD MARKETSWhich disease will be eradicated next in humans?
462,5 €Polio: 26.7%MANIFOLD MARKETS
MANIFOLD MARKETSIn diesen Themen aktiv
Verwandte Nachrichten
Chainalysis reveals $100 million peptide market built on cryptoCrypto News
Gray peptide vendors embrace stablecoins as safety fears deepenCrypto News
OpenAI Expands GPT-Rosalind Access with Rosalind BiodefenseBlockchain.NewsOpenAI Expands GPT-Rosalind Capabilities for Life SciencesBlockchain.News
Brian Armstrong’s NewLimit Raises $435M for Human TrialsCrypto NewsRegeln
Retatrutide is a triple agonist hormone/peptide drug developed by Eli Lilly and currently in trial to treat obesity, fatty liver disease, type-2 diabetes, knee osteoarthritis, and more.
- This market will resolve to "Yes" if the U.S.
- Food and Drug Administration (FDA) grants a full or conditional approval for Eli Lilly’s for a drug product whose active ingredient is Eli Lilly’s retatrutide (including any brand name or identifier such as LY3437943) for any use between market creation and December 31, 2026, 11:59 PM ET.
- Otherwise, this market will resolve to "No."
- An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application
- The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs